glp-1 cardiovascular outcome trials receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs | Diabetology fig1.png
Description
Sturrock, N
Specifically, the STEP-4 trials recorded a 10.6% weight loss with semaglutide [8,9]
Efpeglenatide and cardiovascular outcomes in type 2 diabetes
The answer lies in the psychology of diabetes
